Twist Bioscience (TWST) Receivables - Net (2018 - 2026)

Twist Bioscience (TWST) has reported Receivables - Net for 9 consecutive years, with $65.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Net rose 30.49% year-over-year to $65.1 million in Q2 2026; TTM through Jun 2026 was $65.1 million, a 30.49% increase from a year earlier, with the FY2025 full-year figure at $57.0 million, up 63.36% from the prior year.
• Receivables - Net was $65.1 million for Q2 2026 at Twist Bioscience, up from $64.2 million in the prior quarter.
• Over five years, Receivables - Net peaked at $65.1 million in Q2 2026 and troughed at $32.0 million in Q2 2024.
• A 5-year average of $45.0 million and a median of $43.3 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net slipped 25.31% in 2024 and surged 63.36% in 2025, its largest moves.
• Over 5 years, Receivables - Net stood at $44.4 million in 2022, then declined by 20.44% to $35.4 million in 2023, then gained by 11.2% to $39.3 million in 2024, then grew by 27.34% to $50.1 million in 2025, then advanced by 29.95% to $65.1 million in 2026.
• The last three Receivables - Net figures came in at $65.1 million (Q2 2026), $64.2 million (Q1 2026), and $50.1 million (Q4 2025), per Business Quant data.